Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-13.49M
Cash
25.93M
Avg Qtr Burn
-8.70M
Short % of Float
0.57%
Insider Ownership
40.30%
Institutional Own.
1.19%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vebreltinib (APL-101) Details Non-small cell lung carcinoma | NDA FDA meeting | |
Uproleselan (APL-106) Details Acute myeloid leukemia | Phase 3 Data readout | |
Vebreltinib (APL-101) Details Glioblastoma | Phase 2 Update |